Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 16/20 | 0.68 |
| ▸ | PARP15 | Q460N3 | 6/20 | 0.59 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.59 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.55 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.55 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1787654 | 0.95 | PARP10 (0.62) | PARP10PARP15PARP2PARP4PARP14 | |
| SCHEMBL1977030 | 0.92 | PARP10 (0.68) | PARP10PARP15PARP2PARP4PARP14 | |
| SCHEMBL3082936 | 0.91 | PARP10 (0.66) | PARP10PARP15PARP2PARP4PARP14 | |
| SCHEMBL27428054 | 0.84 | GAA (0.59) | PARP10KMT2A | |
| SCHEMBL27972513 | 0.84 | PARP10 (0.66) | PARP10PARP15PARP2PARP4PARP14 | |
| SCHEMBL6122034 | 0.82 | PARP10 (0.70) | PARP10PARP15PARP2PARP4PARP14 | |
| SCHEMBL77571 | 0.82 | PARP10 (0.70) | PARP10PARP15PARP2PARP4PARP14 | |
| SCHEMBL1874960 | 0.82 | L3MBTL1 (0.50) | PARP10ALDH1A1PRSS1 | |
| SCHEMBL6838614 | 0.82 | PKM (0.69) | ALDH1A1 | |
| SCHEMBL4687508 | 0.81 | PARP10 (0.68) | PARP10PARP15PARP2PARP4PARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790720-B2 | Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses | UCB PHARMA, S.A. (BE) | 2010-09-07 | — | — | US | disclosed |
| US-20080275046-A1 | Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2008-11-06 | — | — | US | disclosed |
| EP-1866293-A1 | COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB Pharma, S.A. (BE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006103045-A1 | COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB PHARMA S.A. (BE) | 2006-10-05 | — | — | WO | disclosed |
| CN-1019801-B | Antiarrhythmic and preparation method thereof | PFIZER LTD (GB) | 1992-12-30 | — | — | CN | disclosed |
| EP-0245997-B1 | N-SUBSTITUTED P-AMINOETHYLSULPHON ANILIDES AS ANTIARRHYTHMIC AGENTS, AND INTERMEDIATES THEREFOR | Pfizer Limited (GB) | 1992-04-15 | — | — | EP | disclosed |
| US-5079248-A | Antifibrillatory agents; side effect reduction | PFIZER INC. (US) | 1992-01-07 | — | — | US | disclosed |
| US-4959366-A | Anti-arrhythmic agents | PFIZER INC. (US) | 1990-09-25 | — | — | US | disclosed |
| EP-0245997-A2 | N-substituted p-aminoethylsulphon anilides as antiarrhythmic agents, and intermediates therefor | Pfizer Limited (GB) | 1987-11-19 | — | — | EP | disclosed |
| CN-87103300-A | Antiarrhythmic and preparation method thereof | — | 1987-11-11 | — | — | CN | disclosed |
| US-4636500-A | N-(phenoxyalkyl)imidazoles as selective inhibitors of the thromboxane synthetase enzyme and pharmaceutical compositions thereof | PFIZER INC. (US) | 1987-01-13 | — | — | US | disclosed |
| US-4602016-A | N-(phenoxyalkyl)imidazoles as selective inhibitors of the thromboxane synthetase enzyme and pharmaceutical compositions thereof | PFIZER INC. (US) | 1986-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275046-A1 | Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses | OXER1, OXTR, OGFR | PARP10 4476/4885PARP15 3767/4885PARP2 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.